ABSTRACT
INTRODUCTION
Approximately 80% of lung cancer cases have been classified as non-small cell lung carcinoma (NSCLC), which can be further divided into subtypes according to specific histology such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [1] . Among these pathological subtypes, adenocarcinoma is the most common subtype; which occurs in more than half of NSCLC patients. Furthermore, adenocarcinoma is more aggressive than other NSCLC subtypes, and is often associated with rapid disease progression and early distant metastasis [2, 3] .
Brain metastases (BM) develop in 22-54% of NSCLC patients during the disease course. Studies have shown that the incidence of BM is higher with adenocarcinoma than with the other subtypes of NSCLC [3, 4] . Approximately 45-52% of patients with lung adenocarcinoma develop BM at some point in their disease course, which compares unfavorably with a less than 20% incidence of BM for squamous cell carcinoma [5, 6] . In general, the prognosis for patients with BM remains poor, with a median overall survival (OS) of 2-3 months when treated with systemic corticosteroid alone, and a median OS of 3-6 months when treated with whole brain radiation therapy (WBRT) [7, 8] .
Research Paper
Recently, several studies have reported the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for NSCLC patients with BM. The median OS of patients with BM significantly improved with TKI treatment, which ranged from 11.8 to 18.8 months [9] [10] [11] . Therefore, the BM treatment in this patient population has been guided by the EGFR mutation status.
Among all subtypes of NSCLC, EGFR mutations are predominantly found in adenocarcinomas [12] . The detection of EGFR mutations sensitizing L858R and deletion 19 may warrant treatment with TKIs such as gefitinib, erlotinib and icotinib for patients with advanced pulmonary adenocarcinoma. EGFR signaling pathways in lung cancer have been reported to promote angiogenesis, cellular proliferation and epithelial-mesenchymal transition (EMT); and all of which may mediate oncogenic progression and metastasis [13] [14] [15] . The biological characteristics of EGFR may also reflect the pattern of metastasis. Studies have demonstrated an association between EGFR genetic alterations and distant metastases in patients with breast cancer [16, 17] . Furthermore, in patients with pulmonary adenocarcinomas, different pulmonary metastatic patterns in EGFR-mutated tumors have also been reported [18] . Despite these findings, a clear relationship between EGFR mutation and the BM of lung adenocarcinomas remains to be determined. Some studies have suggested that patients with EGFR mutations may have a higher incidence of BM than patients without EGFR mutations [11, 19, 20] . However, these were not supported by other studies [21, 22] . Due to the small sample size and low numbers of patients included for EGFR mutation analyses in these studies, it was not possible to fully answer this question.
The purposes of this study were to explore the potential correlation between EGFR mutation status and the risk of BM in patients with pulmonary adenocarcinoma, and to compare the OS of pulmonary adenocarcinoma patients with BM according to their EGFR mutation status.
RESULTS

Patient characteristics
A total of 234 patients with a median age of 57.5 years (range: 27-87 years) at initial diagnosis were consecutively enrolled into this study. Patient characteristics are summarized in Table 1 . Among these patients, 76 (32.5%) had documented BM, 39 (16.7%) had initial BM, and 37 (15.8%) had subsequent BM.
A total of 108 patients had EGFR mutations. Among them, 56 (51.9%) patients had exon 19 deletion, 44 (40.7%) patients had exon 21 L858R point mutation, and eight (7.4%) patients had mutations in other sites (three with exon 20 mutation, two with exon 18 mutation, and three with double mutations).
EGFR mutation status and baseline patient characteristics
As shown in Table 1 
EGFR mutation status and characteristics of BM
In order to investigate the potential correlations between the characteristics of BM and EGFR mutation, analyses were performed in patients with final BM stratified by EGFR mutation status (n=76). Representative results of brain magnetic resonance imaging (MRI) scans in patients with wild-type EGFR or EGFR mutations are shown in Figure 1 . The numbers and sizes of the largest metastatic brain lesion between the different EGFR mutation status groups are detailed in Table 2 . (Figure 2A ).
Risk factors for initial BM
EGFR-TKIs sensitive mutation and BM
Among various EGFR mutations,exon19 deletion and exon 21 L858R point mutation are EGFR TKI sensitive mutations. In order to compare BM incidences associated with these two mutations, subgroup analyses were performed in patients with exon 19 deletion (56 patients) and exon 21 L858R point mutation. The incidences of BM were not significantly different between these two subgroups of patients either at initial diagnosis (21.4% for exon 19 vs. 27.3% for exon 21, P=0.638) or at last follow-up (44.6% for exon 19 vs. 45.5% for exon 21, P=0.935). In addition, there were no between-subgroup differences in the 1-, 2-and 3-year accumulative rates of BM (18.5% for exon 19 vs. 23.3% for exon 21, 44.5% for exon 19 vs. 36.1% for exon 21, and 44.5% for exon 19 vs. 57.4% for exon 21; at 1, 2 and 3 years, respectively; P=0.619) ( Figure 2B ).
OS of patients after diagnosis of BM with mutated and wild-type EGFR
Seventy-six patients had final BM in this retrospective analysis. Table 5 shows the baseline characteristics of these patients stratified by EGFR mutation status (two groups). The rates of radiotherapy for BM were similar in both groups (P=0.704). However, chemotherapy was more frequently administered in the wild-type EGFR group than in the EGFR-mutant group ( 
DISCUSSION
Adenocarcinoma is the most common NSCLC subtype. Studies have shown that adenocarcinoma histology is associated with a significantly higher incidence of BM than other subtypes of NSCLC [1, 23, 24] . In this study, we retrospectively evaluated the different features of BM according to EGFR mutation status in patients with pulmonary adenocarcinoma. Our results revealed that patients with EGFR-mutant tumors had a higher incidence of BM than patients with EGFR wild-type tumors both at the time of diagnosis and during the disease course. Brain metastases in patients with EGFR mutations were found to be larger and more diffuse than in patients with wild-type EGFR. To our knowledge, our research may represent the largest cohort study that analyzed the relationship between EGFR mutation status and BM in Chinese lung adenocarcinoma patients.
The frequency of EGFR mutation in pulmonary adenocarcinoma may vary in different ethnic populations. In East Asian patients, the reported EGFR mutation rate is 40%-60% [25] . In our study, EGFR mutation rate was 46.2%; and the most common mutations occurred at exon 19 and exon 21, which were similar to previously published data. Female pulmonary adenocarcinomas patients and never-smokers were reported to have a higher frequency of EGFR mutations [26] , which was also in line with our study results ( Table 1 ). The prevalence of EGFR mutation in Caucasians is less than 15% according to one report [27] , which is much lower than that in the Asian population. The low prevalence of EGFR mutations in the Caucasian population may be the reason that some studies in nonAsian regions were unable to identify any difference in BM risk in patients with or without EGFR mutations [21, 22] . Abbreviations: BM= brain metastases; CI= confidence interval; ECMO= extracranial metastases only; EGFR= epidermal growth factor receptor; N= node; T= tumor; OR= odd ratio. This is the first study to suggest that Chinese pulmonary adenocarcinoma patients with EGFR mutations may be more prone to the development of BM, but not ECMO, compared to patients with wild-type EGFR, both at initial diagnosis and during the course of the disease. Previous studies have shown the impact of EGFR mutation on BM, however, the potential relationship between EGFR mutation and extracranial metastases remains unreported [28, 29] . One study evaluated the impact of EGFR mutation on lung and bone metastases, and found that patients with EGFR mutations had elevated risks for lung and bone metastases [30] . The mechanism for BM may be different from that for metastases to other sites of the body. In order to successfully metastasize to the brain, tumor cells need to have special abilities to cross the blood brain barrier (BBB) and form colonies in the brain. Therefore, in this study, we distinguished all distant metastases without BM from BM, and classified these as ECMO. Future research should be directed to analyze the potential relationship between EGFR mutation status and ECMO to different organ sites.
Further analysis of data from patients with BM revealed that EGFR mutation was significantly associated with increased numbers and sizes of metastatic lesions in the brain. However, this was not consistent with the study conducted by Luo et al [29] . Brain imaging methods were not uniform in the study of Luo et al., while patients in our study all received routine brain MRI. This standardized approach minimized potential bias from using different methods for brain imaging.
Moreover, we demonstrated that there was no difference in BM rate between Chinese pulmonary adenocarcinoma patients with EGFR mutations in exon 19 and exon 21. However, another study reported different results. Li et al. [28] found that patients with EGFR mutations at exon 19 had the highest incidence of BM among patients with EGFR mutations. Selection bias and the small number of patients in the study conducted by Li et al. were possible causes for these differences. Therefore, it may be difficult to draw a conclusion from these data. Future clinical trials with large numbers of patients are needed to provide a definitive conclusion.
Although our study demonstrated the association between EGFR mutation and increased BM incidence, the exact underlying mechanisms remain unclear. Brenda et al. [31] discovered that EGFR signaling elevated C/ EBPβ-LIP expression by increasing the binding activity of CUG-binding protein 1 (CUGBP1) to C/EBPβ mRNA; which may lead to the development of BM. Another study suggested that EGFR signaling may enhance cellular invasion ability mainly through the phosphoinositide 3-kinase/protein kinase B and phospholipase C γ downstream pathways, and EGFR inhibition significantly decreased BM in vivo [32] . Breindel et al. [33] reported that MET activation by EGFR signaling through mitogenactivated protein kinases (MAPK) promoted BM in Abbreviations: BM= brain metastases; CT= chemotherapy; ECOG PS= Eastern Cooperative Oncology Group Performance status; EGFR= epidermal growth factor receptor; EGFR-TKIs= epidermal growth factor receptor tyrosine kinase inhibitors; RT= radiotherapy for brain metastases. NSCLC. EGFR mutation in lung cancer was often found to result in the activation of signal transducers and activators of transcription 3 (STAT3) [34, 35] . Recently, Singh et al. [36] identified STAT3 as an upregulator of lung-to-brain metastases. According to this study, the activation of the STAT3 signal pathway by EGFR mutation may contribute to increased BM risk for patients with EGFR mutations. Although these studies have provided some insights into the mechanisms underlying the increased BM risk associated with pulmonary adenocarcinomas with EGFR mutations, further investigations are needed to elucidate the exact role of EGFR in BM at the molecular level. Previous studies have suggested that EFGR-TKIs treatment may be effective in delaying and/or preventing BM in NSCLC patients with EGFR mutations [37, 38] . However, in our study, EFGR-TKIs treatment was not significantly associated with a decreased risk of subsequent BM. This negative result may be attributed to the relatively small number of patients with EGFR mutations (30/83, 36.1%), who were treated with EFGRTKIs prior to the development of subsequent BM. Further studies are warranted to clarify this issue. Prophylactic cranial irradiation (PCI) is a standard treatment for small cell lung cancer (SCLC) patients with proven effectiveness. However, in NSCLC patients, the use of PCI only reduced the cumulative incidence of BM, and did not improve OS [39] . This is in part due to differences in tumor biology and genetics across various pathological subtypes of NSCLC. It is perceived that only patients with higher risks of BM may benefit from PCI. Based on our findings, we hypothesize that PCI may also provide benefits for pulmonary adenocarcinoma patients with EGFR mutations (especially in exon 19 or 21), who cannot receive EGFR-TKIs for some reason. Well-designed prospective randomized clinical trials are warranted to validate our presupposition.
It was reported that EGFR mutation was associated with improved survival in NSCLC patients with BM [20] . Our study revealed similar results, in which EGFR mutation was a positive predictive factor for OS in Chinese pulmonary adenocarcinoma patients with BM. However, these results were contradictory to the findings of Lou et al. [29] . According to the study conducted by Lou et al., EGFR mutation status had no influence on progression free survival (PFS) or OS in Chinese NSCLC patients with BM (n=136). One possible explanation for this discrepancy is the use of EGFR-TKIs in patients with EGFR mutations, which may contribute to an improved OS. In the study of Lou et al., less than 10% of patients with EGFR mutations received EGFR-TKI treatment; while in our study, more than 40% of EGFR mutation patients with BM were treated with EGFR-TKIs. In several previous studies [9] [10] [11] 40] , patients who received EGFR-TKIs at any time after the diagnosis of BM survived longer than patients who did not receive this treatment. In our study, EGFRTKIs were administered more frequently in patients with BM and EGFR-mutant, compared with BM and wild-type EGFR; which may prolong OS.
There were some limitations in this study. First, this is a retrospective study, which may introduce potential bias resulting from uncontrolled factors involved in the complex treatment regimens such as treatment duration and concurrent therapy, since patients with lung adenocarcinoma received a wide variety of treatments. Second, the relatively low number of patients in this study may be insufficient to clearly define whether there is a strong link between EGFR mutations and BM. Third, the EGFR mutation status was evaluated by using samples from the original lung tumor rather than from the BM lesions, but the potential heterogeneity of tumor tissues was not taken into consideration in this study. Fourth, patients in this study did not receive periodic brain imaging scans; therefore the timing and incidence of BM may be inaccurate for asymptomatic patients. Fifth, since the neurological symptoms and deficit scores of patients were not available in the database, we were unable to evaluate the quality of life of patients with BM. Finally, this study did not evaluate the relationship between BM and other clinically relevant genetic changes such as KRAS mutation, ALK rearrangement, and MET amplification.
In conclusion, in this retrospective study, we have demonstrated that BM was more common among patients with EGFR-mutant lung adenocarcinoma (vs. wild-type EGFR lung adenocarcinoma). Thus, BM may represent as one of the distinct clinical features for EGFR-mutant tumors. EGFR mutation was shown to be an independent predictive and prognostic risk factor of BM for patients with lung adenocarcinoma, as well as a positive predictive factor for OS in patients with BM. Further molecular studies of EGFR-mutant tumors are needed to elucidate the mechanisms underlying this discovery.
MATERIALS AND METHODS
Patients
Inclusion criteria were as follows: (1) patients with pathologically confirmed lung adenocarcinoma, who underwent EGFR mutation screening and treatment at our institution between March 2007 and November 2014; (2) prior to the treatment, all patients who received initial staging work-up that consists of chest computed tomography (CT) scan, abdominal ultrasound/CT, bone scan and MRI of the brain; (3) the clinical stage was classified using the tumor, node, metastasis (TNM) system proposed by the American Joint Committee on Cancer (7 th edition). A total of 234 patients were included into this study. The study protocol was reviewed and approved by the Review Board and Ethics Committee of Hubei Cancer Hospital. This research was carried out in accordance with approved guidelines and the Declaration of Helsinki.
Follow up and data collection
Patients were evaluated every three months for the first two years, then every 4-6 months for the next three years, and annually thereafter. Each follow-up evaluation consisted of history and physical examination, imaging studies including chest CT and abdominal ultrasound/ CT, and other clinical examinations that were deemed necessary. Routine brain imaging was not performed during the follow-up period. Contrast-enhanced brain MRI scan was performed when BM was suspected. Disease progression and the sites of metastasis were determined by either imaging or histologic analysis, or both.
Clinical characteristics including age, gender, smoking history, treatment, time to progress to BM, the number of BM, the size of the largest metastatic brain lesion, survival time and so on, were obtained from medical records. Distant metastases were categorized as metastasis to the brain (patients with brain and extracranial metastases were included) or metastasis to extracranial sites only. BM at initial diagnosis was defined as "initial BM", and BM found during and after treatment was recorded as "subsequent BM". At the end of the follow-up, total BM (initial BM + subsequent BM) was documented as "final BM". Similarly, according to the different timing of diagnosis, ECMO were recorded as "initial ECMO", "subsequent ECMO" or "final ECMO". The time to subsequent BM was calculated as the time between the date of the initial diagnosis and the date when BM was documented radiographically. The OS of patients after the diagnosis of final BM was calculated as the time between the date of BM diagnosis and the date of the last follow-up or death from any cause.
EGFR mutation testing
EGFR gene mutations were analyzed in paraffinembedded tissue sections from the primary tumor. Tumor tissue was scraped from glass slides under direct visualization or under a dissecting microscope, and Genomic DNA was extracted with a HGN-tq0850 DNA Kit (Hygeianey Bioscience Co. Ltd., Wuhan, China). EGFR mutations were detected using the HGN EGFR Mutations Detection Kit (Hygeianey Bioscience Co. Ltd., Wuhan, China) based on the principle of the peptide nucleic acid-locked nucleic acidpolymerase chain reaction clamp method [41] . The assay was carried out using the ABI 7500 (Applied Biosystems, Foster City, CA, USA) real-time polymerase chain reaction system, according to manufacturer's protocol. The representative results of the EGFR mutation test are shown in Figure 4 .
Statistical analysis
All data were processed with SPSS 19.0 (IBM SPSS Inc., Chicago, IL, USA). EGFR mutation status and BM frequency in different groups were compared using Chi-square test. Clinical factors known to be associated with initial BM were included in the logistic regression analysis. Univariate and multivariate analyses of risk factors for subsequent BM were performed using the log-rank test and Cox regression, respectively. The Kaplan-Meier method was used to calculate the time to subsequent BM and draw the survival curves. The number and the largest size of brain metastatic lesion in different EGFR mutation status groups were also compared using the Chi-square test. A 2-sided P<0.05 was considered statistically significant.
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